Patient demographics and disease characteristics
| . | Patients (N = 14) . |
|---|---|
| Age, median (range), y | 58.5 (27-86) |
| Sex, n (%) | |
| Male | 11 (79) |
| Female | 3 (21) |
| Race, n (%) | |
| White | 13 (93) |
| African American/black | 1 (7) |
| Lymphoma subtype | |
| DLBCL* | 10 |
| Transformed DLBCL | 4 |
| IPI at diagnosis, n (%) | |
| Low (0, 1) | 3 (21) |
| Low-intermediate (2) | 3 (21) |
| High-intermediate (3) | 5 (36) |
| Unknown | 3 (21) |
| Advanced stage (III/IV) at diagnosis | 4 (29) |
| c-MYC rearrangement, n (%) | |
| Yes | 3 (21) |
| No | 8 (57) |
| Unknown | 3 (21) |
| Median interval between diagnosis and start of loncastuximab tesirine (range), mo | 21.5 (6.8-258) |
| Best response to loncastuximab tesirine, n (%) | |
| Complete response | 1 (7) |
| Partial response | 5 (36) |
| . | Patients (N = 14) . |
|---|---|
| Age, median (range), y | 58.5 (27-86) |
| Sex, n (%) | |
| Male | 11 (79) |
| Female | 3 (21) |
| Race, n (%) | |
| White | 13 (93) |
| African American/black | 1 (7) |
| Lymphoma subtype | |
| DLBCL* | 10 |
| Transformed DLBCL | 4 |
| IPI at diagnosis, n (%) | |
| Low (0, 1) | 3 (21) |
| Low-intermediate (2) | 3 (21) |
| High-intermediate (3) | 5 (36) |
| Unknown | 3 (21) |
| Advanced stage (III/IV) at diagnosis | 4 (29) |
| c-MYC rearrangement, n (%) | |
| Yes | 3 (21) |
| No | 8 (57) |
| Unknown | 3 (21) |
| Median interval between diagnosis and start of loncastuximab tesirine (range), mo | 21.5 (6.8-258) |
| Best response to loncastuximab tesirine, n (%) | |
| Complete response | 1 (7) |
| Partial response | 5 (36) |
Percentages may not add up to 100 due to rounding.
IPI, International Prognostic Index.
One patient had mediastinal large B-cell lymphoma.